Clinical trials
Metastatic Castrate Resistant Prostate Cancer (mCRPC) clinical trials
Below are recruiting metastatic castrate resistant prostate cancer (mcrpc) clinical trials, each written for real people, not researchers. We’re tracking 163 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07096999Recruiting
PET scan to plan treatment for prostate cancer
This trial is for men with metastatic castration-resistant prostate cancer who are already scheduled to receive a treatment called Pluvicto. It uses an extra scan (SPECT/CT) to better measure how the treatment reaches the tumors, which could help personalize dosing and improve safety.
Ann Arbor, MichiganAges 18 years+ - NCT07103018RecruitingPhase 1
Study of KTX-2001 for men with advanced prostate cancer
This trial tests a new drug called KTX-2001, possibly combined with another drug (darolutamide), for men whose prostate cancer has spread and stopped responding to standard hormone treatments. The goal is to see if it can help shrink tumors or slow the cancer's growth.
San Francisco, CaliforniaAges 18 years+ - NCT06971211RecruitingPhase 2
Radiation and drug combo for advanced prostate cancer
This trial combines radiation therapy with two drugs (fluzopanib and abiraterone acetate) to treat men with metastatic castration-resistant prostate cancer that hasn't been treated yet. The goal is to see if this triple approach helps slow the cancer's growth.
Shenyang, LiaoningAges 18 years+ - NCT07093801Recruiting
Study of lutetium-177-PSMA-617 for advanced prostate cancer
This study is observing how well the treatment lutetium-177-PSMA-617 works in people with metastatic castration-resistant prostate cancer. It aims to gather real-world information about its effectiveness and safety.
Alessandria, ALAges 18–99 - NCT07093866RecruitingPhase 2
Targeted drug combo for advanced prostate cancer
This trial tests a combination of two drugs—disitamab vedotin (a targeted antibody-drug that attacks HER2-positive cancer cells) and abiraterone (a hormone therapy)—to see if they can slow or shrink prostate cancer that has spread and become resistant to standard treatments.
Nanjing, JiangsuAges 18–75 - NCT06972628RecruitingPhase 2
177Lu-PSMA-617 for advanced prostate cancer with bone spread
This trial tests a radioactive drug called 177Lu-PSMA-617 to see if it can help men with metastatic castration-resistant prostate cancer that has spread to the bones in a specific pattern (superscan). It's for patients who have already tried hormone therapy and have PSMA-positive tumors.
Houston, TexasAges 18 years+ - NCT07038304RecruitingPhase 2
Radiation for cancer growth in prostate cancer that stopped responding to hormones
This trial tests whether giving precise radiation to a few spots of cancer growth can help control prostate cancer that has stopped responding to hormone therapy. It is for people with up to 3 growing or new spots of cancer on a special scan.
GroningenAges 18 years+ - NCT07015138Recruiting
Comparing two radiation approaches for prostate cancer that has spread a little
This trial is testing whether giving radiation to all spots of cancer that show up on a PSMA PET scan works better than giving radiation only to the main tumor in the prostate. It is for men whose prostate cancer has spread to a few other places (up to 10 spots).
Beijing, Beijing MunicipalityAges 18–85 - NCT07005154RecruitingPhase 2
Study of ASP5541 for metastatic prostate cancer
This study tests an experimental drug called ASP5541 for men with metastatic prostate cancer (either hormone-sensitive or castration-resistant). It aims to see if the drug can slow cancer growth and improve outcomes when added to standard hormone therapy.
Huntsville, AlabamaAges 18 years+ - NCT07002320RecruitingPhase 1/Phase 2
Testing SX-682 plus apalutamide for advanced prostate cancer
This trial tests a new combination of two drugs (SX-682 and apalutamide) for men with metastatic prostate cancer that is no longer responding to standard hormone therapy. The goal is to see if adding SX-682 can help apalutamide work better.
BellinzonaAges 18 years+ - NCT06943495RecruitingPhase 1
Personalized vs. standard dose of a targeted therapy for prostate cancer
This trial compares two ways of giving a radioactive drug (177Lu-PSMA-617) designed to find and destroy prostate cancer cells. It tests whether adjusting the dose based on your individual tumor’s activity works better than a fixed standard dose.
Québec, QuebecAges 18 years+ - NCT06863272RecruitingPhase 1/Phase 2
Study of ifinatamab deruxtecan for advanced prostate cancer
This trial tests a new drug, ifinatamab deruxtecan, either alone or in combination with other treatments, for men with metastatic castrate-resistant prostate cancer that has worsened despite hormone therapy. It aims to see if this approach can help shrink or slow the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT06866938RecruitingPhase 2
Second course of PSMA-targeted radiation for prostate cancer
This study tests giving the targeted radiation drug [177Lu]Lu-PSMA again to men whose prostate cancer has started growing after an earlier course of the same treatment. It aims to see if a second round can control the cancer again.
BordeauxAges 18 years+ - NCT06842498RecruitingPhase 2
FG-3246 for advanced prostate cancer
This trial tests a new drug called FG-3246, which targets a protein (CD46) on prostate cancer cells. It's for men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy, and who have had limited prior treatments.
Goodyear, ArizonaAges 18 years+ - NCT06844383RecruitingPhase 2
Talazoparib with or without enzalutamide for prostate cancer after prior treatment
This study tests a drug called talazoparib, either alone or combined with enzalutamide, in people with prostate cancer that has spread and has a specific genetic change. The goal is to see if this treatment can help control the cancer after previous therapies have stopped working.
Duarte, CaliforniaAges 18 years+ - NCT06835218Recruiting
Prostate cancer real-world evidence registry
This study collects information from men with prostate cancer to better understand how different treatments work in real life. It follows patients when they start a new treatment and can help improve future care.
Freiburg im Breisgau, Baden-WurttembergAges 18 years+ - NCT06801236RecruitingPhase 1
A new drug for advanced prostate cancer that has stopped responding to treatment
This early-phase trial tests a new study drug called ACE-232 for men with advanced prostate cancer that has stopped responding to standard hormone therapy and chemotherapy. It aims to see if the drug is safe and may help slow the cancer.
La Jolla, CaliforniaAges 18 years+ - NCT06784193RecruitingPhase 1
Study of OP-3136 for advanced solid tumors
This trial tests a new drug, OP-3136, alone or with other drugs, for people with advanced breast cancer, prostate cancer, or lung cancer that has stopped responding to other treatments. It aims to see if OP-3136 is safe and effective.
Gilbert, ArizonaAges 18 years+ - NCT06785636RecruitingPhase 1/Phase 2
New drug combination for advanced prostate cancer
This study tests a new drug (pocenbrodib) alone or combined with another hormone therapy (darolutamide) for men with advanced prostate cancer that has spread. It is for those who have already tried Pluvicto and one other hormone therapy, but not yet chemotherapy.
Fountain Valley, CaliforniaAges 18 years+ - NCT06738303RecruitingPhase 2
Cabazitaxel with or without carboplatin vs lutetium PSMA for prostate cancer
This trial compares two treatment approaches for advanced prostate cancer that has stopped responding to hormone therapy. One group gets chemotherapy (cabazitaxel with or without carboplatin) and the other gets a targeted radiation therapy (177Lu-PSMA-617). The goal is to see which works better.
Cleveland, OhioAges 19 years+ - NCT06705686RecruitingPhase 1
New drug for advanced prostate cancer
This trial tests an experimental drug called (R)-9b for men with a specific type of advanced prostate cancer that has stopped responding to hormone therapy. The goal is to see if this drug can help control the cancer.
Madison, WisconsinAges 18 years+ - NCT06632977RecruitingPhase 2
Matching targeted treatments to your prostate cancer's genetics
This trial is testing whether matching your cancer's specific genetic changes to a targeted treatment can help control metastatic prostate cancer that has stopped responding to standard hormone therapy and chemotherapy. You may receive a drug, a radioactive treatment, or a combination based on your tumor's molecular profile.
Birmingham, AlabamaAges 18 years+ - NCT06629779RecruitingPhase 3
Study of Mevrometostat for Advanced Prostate Cancer
This study tests a new drug called mevrometostat for men with a specific type of advanced prostate cancer that has spread and is still growing despite hormone therapy. It aims to see if the drug can help control the cancer.
Chandler, ArizonaAges 18 years+ - NCT06610825RecruitingPhase 2
Enhertu for prostate cancer resistant to hormone therapy
This trial is testing a drug called Enhertu for men whose prostate cancer has spread and is no longer responding to hormone treatments. You may join if you have a tumor sample that can be tested for a protein called HER2.
Washington D.C., District of ColumbiaAges 18 years+
Hear when a new Metastatic Castrate Resistant Prostate Cancer (mCRPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic castrate resistant prostate cancer (mcrpc)?
- Yes. Clin2 currently lists 163 recruiting metastatic castrate resistant prostate cancer (mcrpc) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic castrate resistant prostate cancer (mcrpc) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic castrate resistant prostate cancer (mcrpc) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Castration-resistant Prostate Cancer
- Castrate Resistant Prostate Cancer
- Metastatic Castration-Resistant Prostate Cancer Patients
- Non-metastatic Castration-resistant Prostate Cancer
- Metastatic Prostate Cancer
- Castration-resistant Prostate Cancer
- Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- Prostate Cancer Metastatic Disease
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.